All patients
Age < 65y (younger) Age > 65y Asian type ECOG ⩾ 1 ECOG 0 ECOG 1 Gender, female Gender, male Hemoglobin concentration < 10g/dl hemoglobin concentration > 10g/dl metastasis (liver ) metastasis (lymph node ) PD-L1 < 1% PD-L1 < 5% PD-L1 > 5% PDL1 (TC0 and IC0 : <1% of TC and IC) PDL1 (TC2/3 or IC2/3 : ≥5% of TC or IC) smoker (Current) smoker (Former) smoker (never)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
urothelial cancer (UC) - bladder cancer (BC), atezolizumab based treatment vs. platinum derivate, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results IMvigor-130 (At-arm B vs Ch-armC), 2020 1.02 [0.83; 1.25]
1.02 [0.83 ; 1.25 ] IMvigor-130 (At-arm B vs Ch-armC), 2020 1 0% 760 NA not evaluable DORdetailed results IMvigor-130 (At-arm B vs Ch-armC), 2020 0.21 [0.12; 0.37]
0.21 [0.12 ; 0.37 ] IMvigor-130 (At-arm B vs Ch-armC), 2020 1 0% 256 NA not evaluable objective responses (ORR)detailed results IMvigor-130 (At-arm B vs Ch-armC), 2020 0.38 [0.28; 0.53]
0.38 [0.28 ; 0.53 ] IMvigor-130 (At-arm B vs Ch-armC), 2020 1 0% 760 NA not evaluable AE (any grade)detailed results IMvigor-130 (At-arm B vs Ch-armC), 2020 0.14 [0.05; 0.40]
0.14 [0.05 ; 0.40 ] IMvigor-130 (At-arm B vs Ch-armC), 2020 1 0% 744 NA not evaluable AE (grade 3-4)detailed results IMvigor-130 (At-arm B vs Ch-armC), 2020 0.12 [0.08; 0.17]
0.12 [0.08 ; 0.17 ] IMvigor-130 (At-arm B vs Ch-armC), 2020 1 0% 744 NA not evaluable AE leading to death (grade 5)detailed results IMvigor-130 (At-arm B vs Ch-armC), 2020 1.59 [0.88; 2.87]
1.59 [0.88 ; 2.87 ] IMvigor-130 (At-arm B vs Ch-armC), 2020 1 0% 744 NA not evaluable AE leading to treatment discontinuation (any grade)detailed results IMvigor-130 (At-arm B vs Ch-armC), 2020 0.13 [0.08; 0.21]
0.13 [0.08 ; 0.21 ] IMvigor-130 (At-arm B vs Ch-armC), 2020 1 0% 756 NA not evaluable SAE (any grade)detailed results IMvigor-130 (At-arm B vs Ch-armC), 2020 0.78 [0.59; 1.05]
0.78 [0.59 ; 1.05 ] IMvigor-130 (At-arm B vs Ch-armC), 2020 1 0% 744 NA not evaluable STRAE (any grade)detailed results IMvigor-130 (At-arm B vs Ch-armC), 2020 0.41 [0.28; 0.60]
0.41 [0.28 ; 0.60 ] IMvigor-130 (At-arm B vs Ch-armC), 2020 1 0% 744 NA not evaluable TRAE (any grade)detailed results IMvigor-130 (At-arm B vs Ch-armC), 2020 0.07 [0.04; 0.11]
0.07 [0.04 ; 0.11 ] IMvigor-130 (At-arm B vs Ch-armC), 2020 1 0% 744 NA not evaluable TRAE (grade 3-4)detailed results IMvigor-130 (At-arm B vs Ch-armC), 2020 0.04 [0.03; 0.06]
0.04 [0.03 ; 0.06 ] IMvigor-130 (At-arm B vs Ch-armC), 2020 1 0% 744 NA not evaluable TRAE leading to death (grade 5)detailed results IMvigor-130 (At-arm B vs Ch-armC), 2020 0.82 [0.18; 3.71]
0.82 [0.18 ; 3.71 ] IMvigor-130 (At-arm B vs Ch-armC), 2020 1 0% 744 NA not evaluable Anaemia TRAE (grade 3-4)detailed results IMvigor-130 (At-arm B vs Ch-armC), 2020 0.07 [0.02; 0.30]
0.07 [0.02 ; 0.30 ] IMvigor-130 (At-arm B vs Ch-armC), 2020 1 0% 744 NA not evaluable Asthenia TRAE (grade 3-4)detailed results IMvigor-130 (At-arm B vs Ch-armC), 2020 0.63 [0.18; 2.15]
0.63 [0.18 ; 2.15 ] IMvigor-130 (At-arm B vs Ch-armC), 2020 1 0% 744 NA not evaluable Decreased appetite TRAE (grade 3-4)detailed results IMvigor-130 (At-arm B vs Ch-armC), 2020 2.21 [0.20; 24.48]
2.21 [0.20 ; 24.48 ] IMvigor-130 (At-arm B vs Ch-armC), 2020 1 0% 744 NA not evaluable Fatigue TRAE (grade 3-4)detailed results IMvigor-130 (At-arm B vs Ch-armC), 2020 0.73 [0.12; 4.41]
0.73 [0.12 ; 4.41 ] IMvigor-130 (At-arm B vs Ch-armC), 2020 1 0% 744 NA not evaluable Nausea TRAE (grade 3-4)detailed results IMvigor-130 (At-arm B vs Ch-armC), 2020 0.27 [0.01; 6.11]
0.27 [0.01 ; 6.11 ] IMvigor-130 (At-arm B vs Ch-armC), 2020 1 0% 744 NA not evaluable Neutropenia TRAE (grade 3-4)detailed results IMvigor-130 (At-arm B vs Ch-armC), 2020 0.03 [0.00; 0.52]
0.03 [0.00 ; 0.52 ] IMvigor-130 (At-arm B vs Ch-armC), 2020 1 0% 744 NA not evaluable Pruritus TRAE (grade 3-4)detailed results IMvigor-130 (At-arm B vs Ch-armC), 2020 1.10 [0.02; 55.68]
1.10 [0.02 ; 55.68 ] IMvigor-130 (At-arm B vs Ch-armC), 2020 1 0% 744 NA not evaluable Rash TRAE (grade 3-4)detailed results IMvigor-130 (At-arm B vs Ch-armC), 2020 4.43 [0.20; 98.49]
4.43 [0.20 ; 98.49 ] IMvigor-130 (At-arm B vs Ch-armC), 2020 1 0% 744 NA not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results IMvigor-130 (At-arm B vs Ch-armC), 2020 0.08 [0.01; 0.58]
0.08 [0.01 ; 0.58 ] IMvigor-130 (At-arm B vs Ch-armC), 2020 1 0% 744 NA not evaluable Anaemia AE (grade 3-4)detailed results IMvigor-130 (At-arm B vs Ch-armC), 2020 0.08 [0.05; 0.13]
0.08 [0.05 ; 0.13 ] IMvigor-130 (At-arm B vs Ch-armC), 2020 1 0% 744 NA not evaluable Asthenia AE (grade 3-4)detailed results IMvigor-130 (At-arm B vs Ch-armC), 2020 0.51 [0.24; 1.10]
0.51 [0.24 ; 1.10 ] IMvigor-130 (At-arm B vs Ch-armC), 2020 1 0% 744 NA not evaluable Fatigue AE (grade 3-4)detailed results IMvigor-130 (At-arm B vs Ch-armC), 2020 0.22 [0.09; 0.54]
0.22 [0.09 ; 0.54 ] IMvigor-130 (At-arm B vs Ch-armC), 2020 1 0% 744 NA not evaluable Febrile neutropenia AE (grade 3-4)detailed results IMvigor-130 (At-arm B vs Ch-armC), 2020 0.05 [0.00; 0.92]
0.05 [0.00 ; 0.92 ] IMvigor-130 (At-arm B vs Ch-armC), 2020 1 0% 744 NA not evaluable Hypertension AE (grade 3-4)detailed results IMvigor-130 (At-arm B vs Ch-armC), 2020 0.54 [0.18; 1.61]
0.54 [0.18 ; 1.61 ] IMvigor-130 (At-arm B vs Ch-armC), 2020 1 0% 744 NA not evaluable Leucopenia AE (grade 3-4)detailed results IMvigor-130 (At-arm B vs Ch-armC), 2020 0.02 [0.00; 0.25]
0.02 [0.00 ; 0.25 ] IMvigor-130 (At-arm B vs Ch-armC), 2020 1 0% 744 NA not evaluable Nausea AE (grade 3-4)detailed results IMvigor-130 (At-arm B vs Ch-armC), 2020 0.08 [0.01; 0.58]
0.08 [0.01 ; 0.58 ] IMvigor-130 (At-arm B vs Ch-armC), 2020 1 0% 744 NA not evaluable Neutropenia AE (grade 3-4)detailed results Out of scale IMvigor-130 (At-arm B vs Ch-armC), 2020 0.00 [0.00; 0.05]
0.00 [0.00 ; 0.05 ] IMvigor-130 (At-arm B vs Ch-armC), 2020 1 0% 744 NA not evaluable Thrombocytopenia AE (grade 3-4)detailed results IMvigor-130 (At-arm B vs Ch-armC), 2020 0.01 [0.00; 0.10]
0.01 [0.00 ; 0.10 ] IMvigor-130 (At-arm B vs Ch-armC), 2020 1 0% 744 NA not evaluable Vomiting AE (grade 3-4)detailed results IMvigor-130 (At-arm B vs Ch-armC), 2020 0.10 [0.01; 0.76]
0.10 [0.01 ; 0.76 ] IMvigor-130 (At-arm B vs Ch-armC), 2020 1 0% 744 NA not evaluable 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-09-30 22:59 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 11,288,153,157,290,155,154,289,188,189,239,158,252,253,76,238,236,237
- treatments: 851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866